Evidence map›Paper›PMID 39195328›Full record

ArticleCurrent oncology (Toronto, Ont.)2024

Comparison of Weekly Paclitaxel Regimens in Recurrent Platinum-Resistant Ovarian Cancer: A Single Institution Retrospective Study.

Laurence Morin, Louis-Philippe Grenier, Nicolas Foucault, Éric Lévesque, François Fabi, Eve-Lyne Langlais, Alexandra Sebastianelli, Marianne Lavoie, Marc Lalancette, Marie Plante and 2 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Current oncology (Toronto, Ont.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Laurence MorinMedical Oncology Division, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1J 5B3, Canada.ORCID 0009-0000-7342-0311
Louis-Philippe GrenierMedical Oncology Pharmacy Department, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1J 5B3, Canada.ORCID 0009-0007-6718-6160
Nicolas FoucaultPharmacy Department, Unité de Formation et de Recherche en Santé de Rouen, 76183 Normandie, France.
Éric LévesqueMedical Oncology Division, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1J 5B3, Canada.
François FabiRadio-Oncology Division, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1J 5B3, Canada.
Eve-Lyne LanglaisGynecologic Oncology Division, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1J 5B3, Canada.
Alexandra SebastianelliGynecologic Oncology Division, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1J 5B3, Canada.
Marianne LavoieMedical Oncology Division, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1J 5B3, Canada.
Marc LalancetteMedical Oncology Division, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1J 5B3, Canada.
Marie PlanteGynecologic Oncology Division, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1J 5B3, Canada.ORCID 0000-0002-2298-7913
Mahukpe Narcisse Ulrich SingboCentre de Recherche du Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1E 6W2, Canada.
Vincent CastonguayMedical Oncology Division, Centre Hospitalier Universitaire de Québec-Université Laval, Québec, QC G1J 5B3, Canada.

Funding

Consolidated funds for clinical research of the Hematology-Oncology department, CHU de Québec N/A
6 · The paper itself

Abstract

Weekly paclitaxel (WP) is a chemotherapeutic cornerstone in the management of patients with platinum-resistant ovarian carcinoma. Multiple WP dosing regimens have been used clinically and studied individually. However, no formal comparison of these regimens is available to provide objective guidance in clinical decision making. The primary objective of this study was to compare the cumulative dose of paclitaxel delivered using 80 mg/m

Indexed as

Drug Resistance, NeoplasmOvarian NeoplasmsPaclitaxelAdultAgedAged, 80 and overAntineoplastic Agents, PhytogenicDrug Administration ScheduleFemaleHumansMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesAntineoplastic Agents, PhytogenicPaclitaxelovarian carcinomapaclitaxelplatinum-resistant

Identifiers

PMID39195328
PMCPMC11352914

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.